Evaluation of the neuromuscular blocking properties and side-effects of the two new isoquinolinium bisquaternary compounds (BW.252C64 and BW.403C65).
D000138:Acidosis / Q000378:metabolism; D000471:Alkalosis / Q000378:metabolism; D000777:Anesthetics; D000818:Animals; D002415:Cats; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D004285:Dogs; D005703:Gallamine Triethiodide / Q000494:pharmacology; D005725:Ganglia, Autonomic / Q000187:drug effects; D000882:Haplorhini; D006439:Hemodynamics / Q000187:drug effects; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D007546:Isoquinolines / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects; D008251:Macaca; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects / Q000494:pharmacology*; D011817:Rabbits; D013045:Species Specificity; D013390:Succinylcholine / Q000378:metabolism; D014403:Tubocurarine / Q000494:pharmacology; D014630:Vagus Nerve / Q000187:drug effects
D000777:Anesthetics; D002800:Cholinesterase Inhibitors; D007546:Isoquinolines; D003473:Neuromuscular Nondepolarizing Agents; D013390:Succinylcholine; D005703:Gallamine Triethiodide; D014403:Tubocurarine